ElevateBio nabs $535M to advance CGT technologies

By The Science Advisory Board staff writers

ElevateBio has raised $535 million in financing to advance its cell and gene therapy (CGT) technology platforms, build its network of process development and good manufacturing practice (GMP) manufacturing capacity, and increase its number of industry partnerships.

ElevateBio has created a suite of CGT-enabling technologies, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering technologies. The company is advancing CGTs using its technology-enabled process development and current GMP (cGMP) manufacturing capability, called BaseCamp.

Matrix Capital Management led the series C financing.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?